Herein, the combined treatment of SB505124, a TGF-β1 antagonist, with 2’,3’-cGAMP synergistically enhanced apoptotic marker expression and inhibited tumor growth, presenting a promising combinatorial therapeutic strategy. This evidence concerns the gene TGFB1 and neoplasm.